CN105954085A - Mercury-free hematoxylin staining fluid - Google Patents
Mercury-free hematoxylin staining fluid Download PDFInfo
- Publication number
- CN105954085A CN105954085A CN201610342055.XA CN201610342055A CN105954085A CN 105954085 A CN105954085 A CN 105954085A CN 201610342055 A CN201610342055 A CN 201610342055A CN 105954085 A CN105954085 A CN 105954085A
- Authority
- CN
- China
- Prior art keywords
- haematoxylin
- particle
- dyeing
- mercury
- carbon nano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 title claims abstract description 64
- 239000012530 fluid Substances 0.000 title abstract description 11
- 238000010186 staining Methods 0.000 title abstract 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 39
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 29
- 239000011259 mixed solution Substances 0.000 claims abstract description 21
- 239000007864 aqueous solution Substances 0.000 claims abstract description 17
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 claims abstract description 17
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000012153 distilled water Substances 0.000 claims abstract description 11
- 238000004043 dyeing Methods 0.000 claims description 64
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 claims description 46
- 239000007788 liquid Substances 0.000 claims description 34
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims description 29
- 239000011852 carbon nanoparticle Substances 0.000 claims description 26
- 238000002560 therapeutic procedure Methods 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 8
- 108010077544 Chromatin Proteins 0.000 abstract description 7
- 210000003483 chromatin Anatomy 0.000 abstract description 7
- 210000000633 nuclear envelope Anatomy 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 239000000654 additive Substances 0.000 abstract 2
- 230000000996 additive effect Effects 0.000 abstract 2
- 229940103272 aluminum potassium sulfate Drugs 0.000 abstract 2
- 210000003855 cell nucleus Anatomy 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- 238000000034 method Methods 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 108010089610 Nuclear Proteins Proteins 0.000 description 6
- 102000007999 Nuclear Proteins Human genes 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- HLUCICHZHWJHLL-UHFFFAOYSA-N Haematein Natural products C12=CC=C(O)C(O)=C2OCC2(O)C1=C1C=C(O)C(=O)C=C1C2 HLUCICHZHWJHLL-UHFFFAOYSA-N 0.000 description 5
- HNNSUZPWERIYIL-UHFFFAOYSA-N chembl1730100 Chemical compound O1CC2(O)CC3=CC(O)=C(O)C=C3C2=C2C1=C(O)C(=O)C=C2 HNNSUZPWERIYIL-UHFFFAOYSA-N 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 229910000474 mercury oxide Inorganic materials 0.000 description 4
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229930182559 Natural dye Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- NALMPLUMOWIVJC-UHFFFAOYSA-N n,n,4-trimethylbenzeneamine oxide Chemical compound CC1=CC=C([N+](C)(C)[O-])C=C1 NALMPLUMOWIVJC-UHFFFAOYSA-N 0.000 description 1
- 239000000978 natural dye Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940032753 sodium iodate Drugs 0.000 description 1
- 235000015281 sodium iodate Nutrition 0.000 description 1
- 239000011697 sodium iodate Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
- G01N2001/302—Stain compositions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses mercury-free hematoxylin staining fluid. The mercury-free hematoxylin staining fluid comprises mixed solution and additive components. The mixed solution comprises, by volume, 1000-1500 parts of distilled water, 70-100 parts of glycerin and 40-60 parts of 1-2% periodic acid aqueous solution, the additive components include hematoxylin, aluminum potassium sulfate and citric acid, the final concentration of the hematoxylin in the staining fluid is 6-8 g/L, the final concentration of the aluminum potassium sulfate in the staining fluid is 40-60 g/L, and the final concentration of the citric acid in the staining fluid is 3-6 g/L. The mercury-free hematoxylin staining fluid has the advantages that the mercury-free hematoxylin staining fluid is short in staining time, and good staining effects can be realized by the mercury-free hematoxylin staining fluid; cell nucleuses of cells which are subjected to staining treatment by the aid of the mercury-free hematoxylin staining fluid are clearly stained, and chromatin, nuclear membranes and nucleolus structures of the cells are clear.
Description
Technical field
The invention belongs to pathological experiment technical field, relate to external diagnosis reagent, particularly relate to a kind of nothing
Hydrargyrum haematoxylin dyeing liquid.
Background technology
The histopathologic birth history of existing more than 150 year, in all of hospital, as long as there being operation,
By hospital pathology department, operation tissue samples is made histopathologic diagnosis.
Routine paraffin wax embedding HE stained preparation is the current most basic technology in order to handling tissue samples, it
It is the basis of pathological diagnosis method, is also many new methods, the evaluation reference standard of new technique quality.
Traditional method is in the cylinder that tissue samples is placed treatment fluid, pours into successively or calls in different disposal liquid,
Sample soaks different time by regulation successively in each reagent to be completed to process section, dyeing, mounting etc.,
More than 30 step of omnidistance needs.Whole process uses formaldehyde, dimethylbenzene, mercury oxide, ammonia poisonous in a large number
Evil chemical reagent, pathology technicians places oneself in the midst of toxic environment, and reagent emission of serious pollution of environment for a long time.
And reagent tolerance used is poor, operation complexity, reagent consumption is big, and pathology film-making high-quality sheet is low (complete
State adds up 40～70%), impact diagnosis.Jue great Shuo hospital joins reagent voluntarily simultaneously, lacks unified standard.
Therefore the standardized production of pathology industry organization sample disposal liquid articles for use, Non-toxic, socialization's supply and demand, be
The inexorable trend of industry development.
Haematoxylin is a kind of natural dye, and it is not all right as single dyeing, and its dyeing capacity is weak, must
Must possess two conditions and just can have strong dyeing capacity.One is to produce effective ingredient haematein, and two is to add
Mordant.The generation of haematein need to oxidized could obtain, it is thus achieved that haematein has two kinds of methods, and one is sky
The most ripe, after haematoxylin and other reagent mix, it is exposed to sunlight or bright place, in the effect of natural light
Under, aoxidize maturation at leisure, but the time is longer, typically need about eight weeks.Two is to add chemical reagent to promote
Enter maturation, promote haematoxylin ripe as added mercury oxide or sodium iodate.
HarrisShi haematoxylin is current most widely used dye liquor, owing to its dyeing time is short, effective,
It is welcomed by users very much.But the hypertoxic Harmful chemicals that the mercury oxide wherein used is well recognized as, and
Its collocation method has many points for attention, is not easy to control.
Therefore, research and develop without hydrargyrum haematoxylin dyeing liquid, substitute mercury oxide oxidation technology and have for pathological experiment
There is important meaning.
Summary of the invention
The present invention has designed and developed the liquid of haematoxylin dyeing without hydrargyrum that a kind of dyeing time is short, Color is good.
The technical scheme that the present invention provides is:
A kind of without hydrargyrum haematoxylin dyeing liquid, it is made up of mixed solution and addO-on therapy, wherein, mixes molten
Liquid is made up of the component of volumes below number: distilled water 1000～1500 parts, glycerol 70-100 part,
And 1～the periodic acid aqueous solution 40 of 2%～60 parts, described addO-on therapy comprises following components, each component
Final concentration of in described dyeing liquor: haematoxylin 6～8g/L, aluminium potassium sulfate 40～60g/L and Fructus Citri Limoniae
Acid 3～6g/L.
Preferably, in the described liquid of haematoxylin dyeing without hydrargyrum, it is made up of mixed solution and addO-on therapy,
Wherein, mixed solution is made up of the component of volumes below number: distilled water 1000 parts, glycerol 80 parts
And the periodic acid aqueous solution 60 parts of 1%, described addO-on therapy comprises following components, and each component is described
Final concentration of in dyeing liquor: haematoxylin 7g/L, aluminium potassium sulfate 50g/L and citric acid 5g/L.
Preferably, in the described liquid of haematoxylin dyeing without hydrargyrum, described addO-on therapy also comprises carbon nanometer
Grain, the particle diameter of carbon nano-particle is 10～100nm, and carbon nano-particle is relative to the percent mass of mixed solution
Number is 0.005～0.009%.
Preferably, in the described liquid of haematoxylin dyeing without hydrargyrum, described addO-on therapy also comprises carbon nanometer
Grain, the particle diameter of carbon nano-particle is 40～100nm, and carbon nano-particle is relative to the percent mass of mixed solution
Number is 0.009%.
The liquid dyeing time of haematoxylin dyeing without hydrargyrum of the present invention is short, and Color is good.Institute's dyeing processes
Cell, its nuclear targeting is clear, and chromatin, nuclear membrane and nucleolar structure are clear.Of the present invention
The environmental protection haematoxylin dyeing liquid of type without hydrargyrum can meet routine pathology diagnosis, immunohistochemical diagnosis technology, divide
Sub-biological diagnostic techniques requirement, the tissue effect that dyeing processes is better than conventional art, can substitute oxygen completely
Change the pathological experiment that hydrargyrum is applied to be correlated with as oxidant technique.
Accompanying drawing explanation
Fig. 1 is the intestinal tissue dyeing microphotograph using the liquid of haematoxylin dyeing without hydrargyrum of the present invention dyeing
(amplification is 200 times).
Fig. 2 is the hepatic tissue dyeing microphotograph using the liquid of haematoxylin dyeing without hydrargyrum of the present invention dyeing
(amplification is 200 times).
Detailed description of the invention
The present invention is described in further detail below in conjunction with the accompanying drawings, to make those skilled in the art's reference
Description word can be implemented according to this.
The present invention provides one without hydrargyrum haematoxylin dyeing liquid, and it is made up of mixed solution and addO-on therapy, its
In, mixed solution is made up of the component of volumes below number: distilled water 1000～1500 parts, glycerol
70-100 part, and 1～the periodic acid aqueous solution 40 of 2%～60 parts, described addO-on therapy comprises following group
Point, final concentration of in described dyeing liquor of each component: haematoxylin 6～8g/L, aluminium potassium sulfate 40～60g/L
And citric acid 3～6g/L.
The liquid of haematoxylin dyeing without hydrargyrum that the present invention provides uses the preparation of non-mercury oxidation technology, wherein optimizes matchmaker
The dosage of stain aluminium potassium sulfate, reduces invalid solute concentration too high in solution system；And it is preferred
The reaction temperature of solution and the concentration of oxidant, it is to avoid color unit molecule over oxidation in traditional compound method
The generation oxide-film phenomenon caused；Using periodic acid further is oxidant, it is to avoid metal during oxidation reaction
The generation of ion, makes solution crystallization and solation problem be addressed owing to being formed without nucleus.Cut through tissue
Sheet Coloration experiment proves, nuclear targeting is clear, and chromatin, nuclear membrane and nucleolar structure are clear.
Without the process for preparation of hydrargyrum haematoxylin dyeing liquid in this embodiment, comprise the steps:
1) each component is measured in proportion；
2) aluminium potassium sulfate aqueous solution is heated to 90～95 degree Celsius, wherein, aluminium potassium sulfate aqueous solution
Concentration is 5%；
3) add haematoxylin ethanol solution, mixing, be heated to solution boiling, wherein, haematoxylin without
The concentration of hydrous ethanol solution is 5%；
4) periodic acid solution is added, mixing, boil 5～10 minutes, wherein, periodic acid aqueous solution
Concentration is 1%；
5), after being cooled to room temperature in rapidly solution is moved to cold water, add citric acid and mix.
In a preferred embodiment, in the described liquid of haematoxylin dyeing without hydrargyrum, its by mixed solution and
AddO-on therapy forms, and wherein, mixed solution is made up of the component of volumes below number: distilled water 1000
Part, glycerol 80 parts and the periodic acid aqueous solution 60 parts of 1%, described addO-on therapy comprises following group
Point, final concentration of in described dyeing liquor of each component: haematoxylin 7g/L, aluminium potassium sulfate 50g/L and
Citric acid 5g/L.
In a preferred embodiment, in the described liquid of haematoxylin dyeing without hydrargyrum, described addO-on therapy is also
Comprising carbon nano-particle, the particle diameter of carbon nano-particle is 10～100nm, and carbon nano-particle is molten relative to mixing
The mass percent of liquid is 0.005～0.009%.
Carbon nano-particle is favorably improved haematoxylin stability, extends the storage time of dyeing liquor；Permissible
Avoid the occurrence of the situation of haematein over oxidation；It is attached to it addition, carbon nano-particle is more conducive to haematein
In the intracellular part that must dye, and make coloring stabilized；And carbon nano-particle can also avoid Soviet Union completely
Lignin crystallizes, thus improves the quality of dyeing.
Without the process for preparation of hydrargyrum haematoxylin dyeing liquid in this embodiment, comprise the steps:
1) each component is measured in proportion；
2) aluminium potassium sulfate aqueous solution is heated to 90～95 degree Celsius, wherein, aluminium potassium sulfate aqueous solution
Concentration is 5%；
3) add haematoxylin ethanol solution, mixing, be heated to solution boiling, wherein, haematoxylin without
The concentration of hydrous ethanol solution is 5%；
4) periodic acid solution is added, mixing, boil 5～10 minutes, wherein, periodic acid aqueous solution
Concentration is 1%；
5), after being cooled to room temperature in rapidly solution is moved to cold water, citric acid and carbon nano-particle mixing are added
?.
In a preferred embodiment, in the described liquid of haematoxylin dyeing without hydrargyrum, described addO-on therapy is also
Comprising carbon nano-particle, the particle diameter of carbon nano-particle is 40～100nm, and carbon nano-particle is molten relative to mixing
The mass percent of liquid is 0.009%.
In order to further illustrate technical solution of the present invention, four embodiments presented below.
Embodiment one
In the present embodiment, it is made up of mixed solution and addO-on therapy without hydrargyrum haematoxylin dyeing liquid, wherein, mixed
Close solution to be made up of the component of volumes below number: distilled water 1000mL, glycerol 70mL, and
The periodic acid aqueous solution 40mL of 1%, described addO-on therapy comprises following components, and each component is in described dyeing
Final concentration of in liquid: haematoxylin 6g/L, aluminium potassium sulfate 40g/L and citric acid 3g/L.
The dyeing liquor dyeing time applying this embodiment only needs 6min, and dyeing liquor can persistently use a year and a half.
Proving (please see Figure 1 and Fig. 2) through tissue section strain experiment, nuclear targeting is clear, chromatin, core
Film and nucleolar structure are clear.
Embodiment two
In the present embodiment, it is made up of mixed solution and addO-on therapy without hydrargyrum haematoxylin dyeing liquid, wherein, mixed
Close solution to be made up of the component of volumes below number: distilled water 1500mL, glycerol 100mL, and
The periodic acid aqueous solution 60mL of 2%, described addO-on therapy comprises following components, and each component is in described dyeing
Final concentration of in liquid: haematoxylin 8g/L, aluminium potassium sulfate 60g/L and citric acid 6g/L.
The dyeing liquor dyeing time applying this embodiment only needs 5min, and dyeing liquor can persistently use a year and a half.
Through tissue section strain it is demonstrated experimentally that nuclear targeting is clear, chromatin, nuclear membrane and nucleolar structure are clear.
Embodiment three
In the present embodiment, it is made up of mixed solution and addO-on therapy without hydrargyrum haematoxylin dyeing liquid, wherein, mixed
Close solution to be made up of the component of volumes below number: distilled water 1000mL, glycerol 80mL and 1%
Periodic acid aqueous solution 60mL, described addO-on therapy comprises following components, and each component is in described dyeing liquor
Final concentration of: haematoxylin 7g/L, aluminium potassium sulfate 50g/L, citric acid 5g/L and carbon nano-particle,
The particle diameter of carbon nano-particle is 10～100nm, and carbon nano-particle relative to the mass percent of mixed solution is
0.005%.
The dyeing liquor dyeing time applying this embodiment only needs 3min, and dyeing liquor can persistently use 2 years.
Through tissue section strain it is demonstrated experimentally that nuclear targeting is clear, chromatin, nuclear membrane and nucleolar structure are clear.
Embodiment four
In the present embodiment, it is made up of mixed solution and addO-on therapy without hydrargyrum haematoxylin dyeing liquid, wherein, mixed
Close solution to be made up of the component of volumes below number: distilled water 1000mL, glycerol 80mL and 1%
Periodic acid aqueous solution 60mL, described addO-on therapy comprises following components, and each component is in described dyeing liquor
Final concentration of: haematoxylin 7g/L, aluminium potassium sulfate 50g/L, citric acid 5g/L and carbon nano-particle,
The particle diameter of carbon nano-particle is 40～100nm, and carbon nano-particle relative to the mass percent of mixed solution is
0.009%.
The dyeing liquor dyeing time applying this embodiment only needs 2min, and dyeing liquor can persistently use 2 years.
Through tissue section strain it is demonstrated experimentally that nuclear targeting is clear, chromatin, nuclear membrane and nucleolar structure are clear.
Although embodiment of the present invention are disclosed as above, but it is not restricted to description and embodiment party
Listed utilization in formula, it can be applied to various applicable the field of the invention completely, for being familiar with ability
For the personnel in territory, be easily achieved other amendment, therefore without departing substantially from claim and etc. homotype
Enclosing under limited general concept, the present invention is not limited to specific details and shown here as the figure with description
Example.
Claims (4)
1. one kind without hydrargyrum haematoxylin dyeing liquid, it is characterised in that it is made up of mixed solution and addO-on therapy,
Wherein, mixed solution is made up of the component of volumes below number: distilled water 1000～1500 parts, and the third three
Alcohol 70-100 part, and 1～the periodic acid aqueous solution 40 of 2%～60 parts, described addO-on therapy comprise with
Lower component, final concentration of in described dyeing liquor of each component: haematoxylin 6～8g/L, aluminium potassium sulfate 40～
60g/L and citric acid 3～6g/L.
2. as claimed in claim 1 without hydrargyrum haematoxylin dyeing liquid, it is characterised in that it is by mixed solution
Forming with addO-on therapy, wherein, mixed solution is made up of the component of volumes below number: distilled water 1000
Part, glycerol 80 parts and the periodic acid aqueous solution 60 parts of 1%, described addO-on therapy comprises following group
Point, final concentration of in described dyeing liquor of each component: haematoxylin 7g/L, aluminium potassium sulfate 50g/L and
Citric acid 5g/L.
3. as claimed in claim 2 without hydrargyrum haematoxylin dyeing liquid, it is characterised in that described addO-on therapy
Also comprising carbon nano-particle, the particle diameter of carbon nano-particle is 10～100nm, and carbon nano-particle is relative to mixing
The mass percent of solution is 0.005～0.009%.
4. as claimed in claim 3 without hydrargyrum haematoxylin dyeing liquid, it is characterised in that described addO-on therapy
Also comprising carbon nano-particle, the particle diameter of carbon nano-particle is 40～100nm, and carbon nano-particle is relative to mixing
The mass percent of solution is 0.009%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610342055.XA CN105954085A (en) | 2016-05-20 | 2016-05-20 | Mercury-free hematoxylin staining fluid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610342055.XA CN105954085A (en) | 2016-05-20 | 2016-05-20 | Mercury-free hematoxylin staining fluid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105954085A true CN105954085A (en) | 2016-09-21 |
Family
ID=56909336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610342055.XA Pending CN105954085A (en) | 2016-05-20 | 2016-05-20 | Mercury-free hematoxylin staining fluid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105954085A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109971206A (en) * | 2019-03-25 | 2019-07-05 | 宁波江丰生物信息技术有限公司 | A kind of hematoxylin dye liquor and preparation method thereof |
| CN116426142A (en) * | 2023-04-03 | 2023-07-14 | 安徽信灵检验医学科技股份有限公司 | Hematoxylin staining solution and preparation method and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2372811A (en) * | 2001-02-14 | 2002-09-04 | Hector Cairns | Staining physiological samples |
| CN101251449A (en) * | 2008-04-10 | 2008-08-27 | 山东大学 | Method for staining medical tissue slice |
| CN102167914A (en) * | 2011-01-21 | 2011-08-31 | 哈尔滨格林标本技术开发有限公司 | Mercury-free environment-friendly hematoxylin staining solution |
| CN103694732A (en) * | 2013-12-31 | 2014-04-02 | 江苏省原子医学研究所 | Hematoxylin staining solution and HE (hematoxylin eosin) staining solution containing hematoxylin staining solution |
| CN104977194A (en) * | 2014-04-10 | 2015-10-14 | 北京雷根生物技术有限公司 | Method of accelerating sample treatment with addition of graphene |
-
2016
- 2016-05-20 CN CN201610342055.XA patent/CN105954085A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2372811A (en) * | 2001-02-14 | 2002-09-04 | Hector Cairns | Staining physiological samples |
| CN101251449A (en) * | 2008-04-10 | 2008-08-27 | 山东大学 | Method for staining medical tissue slice |
| CN102167914A (en) * | 2011-01-21 | 2011-08-31 | 哈尔滨格林标本技术开发有限公司 | Mercury-free environment-friendly hematoxylin staining solution |
| CN103694732A (en) * | 2013-12-31 | 2014-04-02 | 江苏省原子医学研究所 | Hematoxylin staining solution and HE (hematoxylin eosin) staining solution containing hematoxylin staining solution |
| CN104977194A (en) * | 2014-04-10 | 2015-10-14 | 北京雷根生物技术有限公司 | Method of accelerating sample treatment with addition of graphene |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109971206A (en) * | 2019-03-25 | 2019-07-05 | 宁波江丰生物信息技术有限公司 | A kind of hematoxylin dye liquor and preparation method thereof |
| CN116426142A (en) * | 2023-04-03 | 2023-07-14 | 安徽信灵检验医学科技股份有限公司 | Hematoxylin staining solution and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102167914A (en) | Mercury-free environment-friendly hematoxylin staining solution | |
| Jordan et al. | Promotion of protocell self-assembly from mixed amphiphiles at the origin of life | |
| Elaissaoui et al. | Effect of coating method on the structure and properties of a novel PbO2 anode for electrochemical oxidation of Amaranth dye | |
| CN103694732A (en) | Hematoxylin staining solution and HE (hematoxylin eosin) staining solution containing hematoxylin staining solution | |
| CN105651580B (en) | A kind of dyed blended liquid in haematoxylin Yihong | |
| CN104155160A (en) | Tissue dewaxing transparent agent free of benzene | |
| CN103725040A (en) | Hematoxylin eosin staining solution and preparation method thereof | |
| CN104941661A (en) | Ordered mesoporous carbon adopting pore wall structure uniformly embedded with metal nanoparticles and controllable preparation method of ordered mesoporous carbon | |
| CN105954085A (en) | Mercury-free hematoxylin staining fluid | |
| CN109580740B (en) | High-specific-surface hollow tubular micron motor, preparation method and application | |
| CN104744967B (en) | A kind of HE dyeing liquors of eosin stains liquid and its liquid containing eosin stains | |
| CN106675524A (en) | Multifunctional phase change material microcapsule and preparation method thereof | |
| CN108101142A (en) | A kind of biomass carbon NH_3-N treating material and preparation method thereof | |
| Bonggotgetsakul et al. | A method for coating a polymer inclusion membrane with palladium nanoparticles | |
| CN109778285A (en) | Aluminum alloy medium-high temperature nickel-free hole sealing agent and preparation method thereof | |
| CN108414328A (en) | A kind of modified form hematoxylin dyeing liquor reagent, preparation method and colouring method | |
| CN105842033A (en) | Formaldehyde-free tissue specimen stationary liquid | |
| CN101608333A (en) | Titanium alloy electrochemical oxidation liquid | |
| US20180200801A1 (en) | Preparation Method for the Nano-silver Particles | |
| CN104977203B (en) | Cold etching agent for displaying dendritic structure morphology of high-carbon steel continuous casting billet and preparation method thereof | |
| CN109490049A (en) | A kind of haematoxylin dyeing liquid and preparation method | |
| CN110736655A (en) | kinds of nucleus DNA staining method | |
| Cao et al. | Skin pigmentation improvement with resveratrol microemulsion gel using polyoxyethylene hydrogenated castor oil | |
| CN107367531B (en) | A kind of electrode surface gas behavior regulation method for electrochemical reaction | |
| CN105987841A (en) | Eosin staining solution |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160921 |
|
| RJ01 | Rejection of invention patent application after publication |